Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market By Type (Metastatic CRPC (mCRPC), Non-Metastaic CRPC (nmCRPC); By Indication (Symptomatic, Mildy Symptomatic, Asymptomatic); By Route of Administration (Oral, Intravenous); By Treatment Type (Hormonal Therapy, Radiation Therapy – External Beam Radiation Therapy, Systematic Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Others); By End User (Hospitals, Speciality Clinics, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Global castration-resistant prostate cancer (CRPC) treatment market was worth US$ 10.2 Bn in 2021, growing at an estimated CAGR of 9.6% over the forecast period. Rising prevalence of chronic diseases like cancer is a major concern for mankind today. Many factors like non-active lifestyle, consumption of unhealthy food and increasing level of pollution is the reason why number of people suffering from such dreadful diseases. Castrate-resistant prostate cancer (CRPC) mainly happens to be a type of cancer that is defined through progression of disease irrespective of androgen depletion therapy (ADT) and is likely to present a constant surge in levels of serum prostate-specific antigen. The resistance becomes evident post 2-3 years of occurrence. Several factors have been contributing to the growth of the global castration-resistant prostate cancer (CRPC) treatment market.
The growth of the global castration-resistant prostate cancer (CRPC) treatment market went downhill during the COVID-19 pandemic. Unavailability for proper medical treatment as majority of hospitals and specialty clinics were full with patients infected with dreadful coronavirus.
Type Outlook
On the basis of type, the global castration-resistant prostate cancer (CRPC) treatment market has been divided into metastatic CRPC (mCRPC) and non-metastatic CRPC (nmCRPC). While in cases where metastases are detected through traditional imaging via computerized tomography (CT) or technetium-99m scintigraphy are known as metastatic castration-resistant prostate cancer (mCRPC). On the other hand, the CRPC that has no radiographic evidence of metastases is known as nonmetastatic CRPC (nmCRPC).
Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue & Forecast, (US$ Million), 2022 – 2030
Indication Outlook
On the basis of indication, the global castration-resistant prostate cancer (CRPC) treatment market has been segmented into symptomatic, mild symptomatic and asymptomatic. Diagnosis of the disease in asymptomatic patients is the most difficult and hence treatment part in such cases is extremely critical.
Route of Administration Outlook
On the basis of route of administration, the global castration-resistant prostate cancer (CRPC) treatment market has been categorised into oral and intravenous. As compared to oral, intravenous route of administering drugs and medicines is more effective. By intravenous way, the drugs can be easily administered and will help creating better impact.
Treatment Type Outlook
On the basis of treatment type, the global castration-resistant prostate cancer (CRPC) treatment market has been bifurcated into hormonal therapy, radiation therapy, chemotherapy, immunotherapy, targeted therapy and others. The radiation therapy segment has been further divided into external beam radiation therapy, and systematic radiation therapy. The hormonal therapy segment accounts for majority of revenue generated by this market. On the other hand, the immunotherapy segment has been forecasted to see growth at the fastest rate.
End Use Outlook
On the basis of end use, the global castration-resistant prostate cancer (CRPC) treatment market has been segmented into hospitals, specialty clinics and others. The hospitals segment dominates in terms of market share as the number of people seeking treatment there are on higher side.
Region Outlook
On the basis of region, the global castration-resistant prostate cancer (CRPC) treatment market has been divided into Latin America, Europe, North America, Asia-Pacific and others. The region of the North America has been a top ranker in terms of contributing to the growth of this market. Presence of advanced treatment centers and specialty clinics in the region is the reason behind this.
Competitive Landscape
The report provides both, qualitative and quantitative research of global castration-resistant prostate cancer (CRPC) treatment market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market are listed below:
- Astellas Pharma Inc.
- Bayer AG
- Pfizer, Inc.
- Johnson & Johnson Services, Inc (Xian Janssen Pharmaceutical Ltd.)
- Sanofi
- Other Market Participants
Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market
By Type
- Metastatic CRPC (mCRPC)
- Non-Metastatic CRPC (nmCRPC)
By Indication
- Symptomatic
- Mildly Symptomatic
- Asymptomatic
By Route of Administration
- Oral
- Intravenous
By Treatment
- Hormonal Therapy
- Radiation Therapy
- External Beam Radiation Therapy
- Systematic Radiation Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Others
By End User
- Hospitals
- Speciality Clinics
- Others
By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1.
Market
Segmentation
1.2.
Years
Considered
1.2.1.
Historic
Years: 2015 - 2020
1.2.2.
Base
Year: 2021
1.2.3.
Forecast
Years: 2022 – 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1.
Primary
Research
3.1.1.
Research
Questionnaire
3.1.2.
Global
Percentage Breakdown
3.1.3.
Primary
Interviews: Key Opinion Leaders (KOLs)
3.2.
Secondary
Research
3.2.1.
Paid
Databases
3.2.2.
Secondary
Sources
3.3.
Market
Size Estimates
3.3.1.
Top-Down
Approach
3.3.2.
Bottom-Up
Approach
3.4.
Data
Triangulation Methodology
3.5.
Research
Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Castration-Resistant Prostate Cancer (CRPC) Treatment Market
6.
Market
Synopsis:Â Castration-Resistant Prostate
Cancer (CRPC) Treatment Market
7.
Castration-Resistant
Prostate Cancer (CRPC) Treatment Market Analysis: Qualitative Perspective
7.1.
Introduction
7.1.1.
Product
Definition
7.1.2.
Industry
Development
7.2.
Market
Dynamics
7.2.1.
Drivers
7.2.2.
Restraints
7.2.3.
Opportunities
7.2.4.
Challenges
7.3.
Trends
in Castration-Resistant Prostate Cancer (CRPC) Treatment Market
7.4.
Market
Determinants Radar Chart
7.5.
Macro-Economic
and Micro-Economic Indicators: Castration-Resistant Prostate Cancer (CRPC)
Treatment Market
7.6.
Porter’s
Five Force Analysis
7.7.
Impact
of Covid-19 on Castration-Resistant Prostate Cancer (CRPC) Treatment Market
8.
Global
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Analysis and
Forecasts, 2022 – 2030
8.1.
Overview
8.1.1.
Global
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
8.2.
Global
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
8.2.1.
Metastatic
CRPC (mCRPC)
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.1.3.
Market
Forecast, 2022 – 2030
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 – 2030
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 – 2030
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 – 2030
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 – 2030
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 – 2030
8.2.2.
Non-Metastatic
CRPC (nmCRPC)
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.2.3.
Market
Forecast, 2022 – 2030
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 – 2030
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 – 2030
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 – 2030
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 – 2030
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 – 2030
8.3.
Key
Segment for Channeling Investments
8.3.1.
By Type
9.
Global
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Analysis and
Forecasts, 2022 – 2030
9.1.
Overview
9.2.
Global
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Indication
9.2.1.
Symptomatic
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.1.3.
Market Forecast,
2022 – 2030
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 – 2030
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 – 2030
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 – 2030
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 – 2030
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 – 2030
9.2.2.
Mildly
Symptomatic
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.2.3.
Market
Forecast, 2022 – 2030
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 – 2030
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 – 2030
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 – 2030
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 – 2030
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 – 2030
9.2.3.
Asymptomatic
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.3.3.
Market
Forecast, 2022 – 2030
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2021
9.2.3.5.1.2. Market Forecast, 2022 – 2030
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2021
9.2.3.5.2.2. Market Forecast, 2022 – 2030
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2021
9.2.3.5.3.2. Market Forecast, 2022 – 2030
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2021
9.2.3.5.4.2. Market Forecast, 2022 – 2030
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2021
9.2.3.5.5.2. Market Forecast, 2022 – 2030
9.3.
Key
Segment for Channeling Investments
9.3.1.
By
Indication
10. Global Castration-Resistant Prostate Cancer
(CRPC) Treatment Market Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Castration-Resistant Prostate Cancer
(CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
10.2.1. Oral
10.2.1.1.
Definition
10.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.1.3.
Market
Forecast, 2022 – 2030
10.2.1.4.
Compound
Annual Growth Rate (CAGR)
10.2.1.5.
Regional
Bifurcation
10.2.1.5.1.
North
America
10.2.1.5.1.1. Market Estimation, 2015 - 2021
10.2.1.5.1.2. Market Forecast, 2022 – 2030
10.2.1.5.2.
Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2021
10.2.1.5.2.2. Market Forecast, 2022 – 2030
10.2.1.5.3.
Asia
Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2021
10.2.1.5.3.2. Market Forecast, 2022 – 2030
10.2.1.5.4.
Middle
East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2021
10.2.1.5.4.2. Market Forecast, 2022 – 2030
10.2.1.5.5.
Latin
America
10.2.1.5.5.1. Market Estimation, 2015 - 2021
10.2.1.5.5.2. Market Forecast, 2022 – 2030
10.2.2. Intravenous
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.2.3.
Market
Forecast, 2022 – 2030
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1.
North
America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 – 2030
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 – 2030
10.2.2.5.3.
Asia
Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 – 2030
10.2.2.5.4.
Middle
East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 – 2030
10.2.2.5.5.
Latin
America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 – 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Route of Administration
11. Global Castration-Resistant Prostate Cancer
(CRPC) Treatment Market Analysis and Forecasts, 2022 – 2030
11.1. Overview
11.2. Global Castration-Resistant Prostate Cancer
(CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment
11.2.1. Hormonal Therapy
11.2.1.1.
Definition
11.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.1.3.
Market
Forecast, 2022 – 2030
11.2.1.4.
Compound
Annual Growth Rate (CAGR)
11.2.1.5.
Regional
Bifurcation
11.2.1.5.1.
North
America
11.2.1.5.1.1. Market Estimation, 2015 - 2021
11.2.1.5.1.2. Market Forecast, 2022 – 2030
11.2.1.5.2.
Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2021
11.2.1.5.2.2. Market Forecast, 2022 – 2030
11.2.1.5.3.
Asia
Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2021
11.2.1.5.3.2. Market Forecast, 2022 – 2030
11.2.1.5.4.
Middle
East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2021
11.2.1.5.4.2. Market Forecast, 2022 – 2030
11.2.1.5.5.
Latin
America
11.2.1.5.5.1. Market Estimation, 2015 - 2021
11.2.1.5.5.2. Market Forecast, 2022 – 2030
11.2.2. Radiation Therapy (Definition, Market
Estimation and Penetration, 2015 - 2021, Market Estimation (2015 - 2021),
Market Forecast (2022 – 2030), Compound Annual Growth Rate (CAGR), Regional
Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin
America) and Information on External Beam Radiation Therapy, Systematic
Radiation Therapy)
11.2.2.1.
External
Beam Radiation Therapy
11.2.2.2.
Systematic
Radiation Therapy
11.2.3. Chemotherapy
11.2.3.1.
Definition
11.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.3.3.
Market
Forecast, 2022 – 2030
11.2.3.4.
Compound
Annual Growth Rate (CAGR)
11.2.3.5.
Regional
Bifurcation
11.2.3.5.1.
North
America
11.2.3.5.1.1. Market Estimation, 2015 - 2021
11.2.3.5.1.2. Market Forecast, 2022 – 2030
11.2.3.5.2.
Europe
11.2.3.5.2.1. Market Estimation, 2015 - 2021
11.2.3.5.2.2. Market Forecast, 2022 – 2030
11.2.3.5.3.
Asia
Pacific
11.2.3.5.3.1. Market Estimation, 2015 - 2021
11.2.3.5.3.2. Market Forecast, 2022 – 2030
11.2.3.5.4.
Middle
East and Africa
11.2.3.5.4.1. Market Estimation, 2015 - 2021
11.2.3.5.4.2. Market Forecast, 2022 – 2030
11.2.3.5.5.
Latin
America
11.2.3.5.5.1. Market Estimation, 2015 - 2021
11.2.3.5.5.2. Market Forecast, 2022 – 2030
11.2.4. Immunotherapy
11.2.4.1.
Definition
11.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.4.3.
Market
Forecast, 2022 – 2030
11.2.4.4.
Compound
Annual Growth Rate (CAGR)
11.2.4.5.
Regional
Bifurcation
11.2.4.5.1.
North
America
11.2.4.5.1.1. Market Estimation, 2015 - 2021
11.2.4.5.1.2. Market Forecast, 2022 – 2030
11.2.4.5.2.
Europe
11.2.4.5.2.1. Market Estimation, 2015 - 2021
11.2.4.5.2.2. Market Forecast, 2022 – 2030
11.2.4.5.3.
Asia
Pacific
11.2.4.5.3.1. Market Estimation, 2015 - 2021
11.2.4.5.3.2. Market Forecast, 2022 – 2030
11.2.4.5.4.
Middle
East and Africa
11.2.4.5.4.1. Market Estimation, 2015 - 2021
11.2.4.5.4.2. Market Forecast, 2022 – 2030
11.2.4.5.5.
Latin
America
11.2.4.5.5.1. Market Estimation, 2015 - 2021
11.2.4.5.5.2. Market Forecast, 2022 – 2030
11.2.5. Targeted Therapy
11.2.5.1.
Definition
11.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.5.3.
Market
Forecast, 2022 – 2030
11.2.5.4.
Compound
Annual Growth Rate (CAGR)
11.2.5.5.
Regional
Bifurcation
11.2.5.5.1.
North
America
11.2.5.5.1.1. Market Estimation, 2015 - 2021
11.2.5.5.1.2. Market Forecast, 2022 – 2030
11.2.5.5.2.
Europe
11.2.5.5.2.1. Market Estimation, 2015 - 2021
11.2.5.5.2.2. Market Forecast, 2022 – 2030
11.2.5.5.3.
Asia
Pacific
11.2.5.5.3.1. Market Estimation, 2015 - 2021
11.2.5.5.3.2. Market Forecast, 2022 – 2030
11.2.5.5.4.
Middle
East and Africa
11.2.5.5.4.1. Market Estimation, 2015 - 2021
11.2.5.5.4.2. Market Forecast, 2022 – 2030
11.2.5.5.5.
Latin
America
11.2.5.5.5.1. Market Estimation, 2015 - 2021
11.2.5.5.5.2. Market Forecast, 2022 – 2030
11.2.6. Others
11.2.6.1.
Definition
11.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.6.3.
Market
Forecast, 2022 – 2030
11.2.6.4.
Compound
Annual Growth Rate (CAGR)
11.2.6.5.
Regional
Bifurcation
11.2.6.5.1.
North
America
11.2.6.5.1.1. Market Estimation, 2015 - 2021
11.2.6.5.1.2. Market Forecast, 2022 – 2030
11.2.6.5.2.
Europe
11.2.6.5.2.1. Market Estimation, 2015 - 2021
11.2.6.5.2.2. Market Forecast, 2022 – 2030
11.2.6.5.3.
Asia
Pacific
11.2.6.5.3.1. Market Estimation, 2015 - 2021
11.2.6.5.3.2. Market Forecast, 2022 – 2030
11.2.6.5.4.
Middle
East and Africa
11.2.6.5.4.1. Market Estimation, 2015 - 2021
11.2.6.5.4.2. Market Forecast, 2022 – 2030
11.2.6.5.5.
Latin
America
11.2.6.5.5.1. Market Estimation, 2015 - 2021
11.2.6.5.5.2. Market Forecast, 2022 – 2030
11.3. Key Segment for Channeling Investments
11.3.1. By Treatment
12. Global Castration-Resistant Prostate Cancer
(CRPC) Treatment Market Analysis and Forecasts, 2022 – 2030
12.1. Overview
12.2. Global Castration-Resistant Prostate Cancer
(CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By End User
12.2.1. Hospitals
12.2.1.1.
Definition
12.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.1.3.
Market
Forecast, 2022 – 2030
12.2.1.4.
Compound
Annual Growth Rate (CAGR)
12.2.1.5.
Regional
Bifurcation
12.2.1.5.1.
North
America
12.2.1.5.1.1. Market Estimation, 2015 - 2021
12.2.1.5.1.2. Market Forecast, 2022 – 2030
12.2.1.5.2.
Europe
12.2.1.5.2.1. Market Estimation, 2015 - 2021
12.2.1.5.2.2. Market Forecast, 2022 – 2030
12.2.1.5.3.
Asia
Pacific
12.2.1.5.3.1. Market Estimation, 2015 - 2021
12.2.1.5.3.2. Market Forecast, 2022 – 2030
12.2.1.5.4.
Middle
East and Africa
12.2.1.5.4.1. Market Estimation, 2015 - 2021
12.2.1.5.4.2. Market Forecast, 2022 – 2030
12.2.1.5.5.
Latin
America
12.2.1.5.5.1. Market Estimation, 2015 - 2021
12.2.1.5.5.2. Market Forecast, 2022 – 2030
12.2.2. Speciality Clinics
12.2.2.1.
Definition
12.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.2.3.
Market
Forecast, 2022 – 2030
12.2.2.4.
Compound
Annual Growth Rate (CAGR)
12.2.2.5.
Regional
Bifurcation
12.2.2.5.1.
North
America
12.2.2.5.1.1. Market Estimation, 2015 - 2021
12.2.2.5.1.2. Market Forecast, 2022 – 2030
12.2.2.5.2.
Europe
12.2.2.5.2.1. Market Estimation, 2015 - 2021
12.2.2.5.2.2. Market Forecast, 2022 – 2030
12.2.2.5.3.
Asia
Pacific
12.2.2.5.3.1. Market Estimation, 2015 - 2021
12.2.2.5.3.2. Market Forecast, 2022 – 2030
12.2.2.5.4.
Middle
East and Africa
12.2.2.5.4.1. Market Estimation, 2015 - 2021
12.2.2.5.4.2. Market Forecast, 2022 – 2030
12.2.2.5.5.
Latin
America
12.2.2.5.5.1. Market Estimation, 2015 - 2021
12.2.2.5.5.2. Market Forecast, 2022 – 2030
12.2.3. Others
12.2.3.1.
Definition
12.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.3.3.
Market
Forecast, 2022 – 2030
12.2.3.4.
Compound
Annual Growth Rate (CAGR)
12.2.3.5.
Regional
Bifurcation
12.2.3.5.1.
North
America
12.2.3.5.1.1. Market Estimation, 2015 - 2021
12.2.3.5.1.2. Market Forecast, 2022 – 2030
12.2.3.5.2.
Europe
12.2.3.5.2.1. Market Estimation, 2015 - 2021
12.2.3.5.2.2. Market Forecast, 2022 – 2030
12.2.3.5.3.
Asia
Pacific
12.2.3.5.3.1. Market Estimation, 2015 - 2021
12.2.3.5.3.2. Market Forecast, 2022 – 2030
12.2.3.5.4.
Middle
East and Africa
12.2.3.5.4.1. Market Estimation, 2015 - 2021
12.2.3.5.4.2. Market Forecast, 2022 – 2030
12.2.3.5.5.
Latin
America
12.2.3.5.5.1. Market Estimation, 2015 - 2021
12.2.3.5.5.2. Market Forecast, 2022 – 2030
12.3. Key Segment for Channeling Investments
12.3.1. By End User
13. North America Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Analysis and Forecasts, 2022 – 2030
13.1. Overview
13.1.1. North America Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn)
13.2. North America Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Type
13.2.1. Metastatic CRPC (mCRPC)
13.2.2. Non-Metastatic CRPC (nmCRPC)
13.3. North America Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Indication
13.3.1. Symptomatic
13.3.2. Mildly Symptomatic
13.3.3. Asymptomatic
13.4. North America Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.4.1. Oral
13.4.2. Intravenous
13.5. North America Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment
13.5.1. Hormonal Therapy
13.5.2. Radiation Therapy
13.5.2.1.
External
Beam Radiation Therapy
13.5.2.2.
Systematic
Radiation Therapy
13.5.3. Chemotherapy
13.5.4. Immunotherapy
13.5.5. Targeted Therapy
13.5.6. Others
13.6. North America Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By End User
13.6.1. Hospitals
13.6.2. Speciality Clinics
13.6.3. Others
13.7. North America Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Country
13.7.1. U.S
13.7.1.1.
U.S
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
13.7.1.1.1.
Metastatic
CRPC (mCRPC)
13.7.1.1.2.
Non-Metastatic
CRPC (nmCRPC)
13.7.1.2.
U.S
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Indication
13.7.1.2.1.
Symptomatic
13.7.1.2.2.
Mildly
Symptomatic
13.7.1.2.3.
Asymptomatic
13.7.1.3.
U.S
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
13.7.1.3.1.
Oral
13.7.1.3.2.
Intravenous
13.7.1.4.
U.S
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
13.7.1.4.1.
Hormonal
Therapy
13.7.1.4.2.
Radiation
Therapy
13.7.1.4.2.1. External Beam Radiation Therapy
13.7.1.4.2.2. Systematic Radiation Therapy
13.7.1.4.3.
Chemotherapy
13.7.1.4.4.
Immunotherapy
13.7.1.4.5.
Targeted
Therapy
13.7.1.4.6.
Others
13.7.1.5.
U.S
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By End User
13.7.1.5.1.
Hospitals
13.7.1.5.2.
Speciality
Clinics
13.7.1.5.3.
Others
13.7.2. Canada
13.7.2.1.
Canada
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
13.7.2.1.1.
Metastatic
CRPC (mCRPC)
13.7.2.1.2.
Non-Metastatic
CRPC (nmCRPC)
13.7.2.2.
Canada
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Indication
13.7.2.2.1.
Symptomatic
13.7.2.2.2.
Mildly
Symptomatic
13.7.2.2.3.
Asymptomatic
13.7.2.3.
Canada
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
13.7.2.3.1.
Oral
13.7.2.3.2.
Intravenous
13.7.2.4.
Canada
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
13.7.2.4.1.
Hormonal
Therapy
13.7.2.4.2.
Radiation
Therapy
13.7.2.4.2.1. External Beam Radiation Therapy
13.7.2.4.2.2. Systematic Radiation Therapy
13.7.2.4.3.
Chemotherapy
13.7.2.4.4.
Immunotherapy
13.7.2.4.5.
Targeted
Therapy
13.7.2.4.6.
Others
13.7.2.5.
Canada
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By End User
13.7.2.5.1.
Hospitals
13.7.2.5.2.
Speciality
Clinics
13.7.2.5.3.
Others
13.7.3. Mexico
13.7.3.1.
Mexico
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
13.7.3.1.1.
Metastatic
CRPC (mCRPC)
13.7.3.1.2.
Non-Metastatic
CRPC (nmCRPC)
13.7.3.2.
Mexico
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Indication
13.7.3.2.1.
Symptomatic
13.7.3.2.2.
Mildly
Symptomatic
13.7.3.2.3.
Asymptomatic
13.7.3.3.
Mexico
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
13.7.3.3.1.
Oral
13.7.3.3.2.
Intravenous
13.7.3.4.
Mexico
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
13.7.3.4.1.
Hormonal
Therapy
13.7.3.4.2.
Radiation
Therapy
13.7.3.4.2.1. External Beam Radiation Therapy
13.7.3.4.2.2. Systematic Radiation Therapy
13.7.3.4.3.
Chemotherapy
13.7.3.4.4.
Immunotherapy
13.7.3.4.5.
Targeted
Therapy
13.7.3.4.6.
Others
13.7.3.5.
Mexico
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By End User
13.7.3.5.1.
Hospitals
13.7.3.5.2.
Speciality
Clinics
13.7.3.5.3.
Others
13.7.4. Rest of North America
13.7.4.1.
Rest of
North America Castration-Resistant Prostate Cancer (CRPC) Treatment Market
Revenue (US$ Mn) and Forecasts, By Type
13.7.4.1.1.
Metastatic
CRPC (mCRPC)
13.7.4.1.2.
Non-Metastatic
CRPC (nmCRPC)
13.7.4.2.
Rest of
North America Castration-Resistant Prostate Cancer (CRPC) Treatment Market
Revenue (US$ Mn) and Forecasts, By Indication
13.7.4.2.1.
Symptomatic
13.7.4.2.2.
Mildly
Symptomatic
13.7.4.2.3.
Asymptomatic
13.7.4.3.
Rest of
North America Castration-Resistant Prostate Cancer (CRPC) Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
13.7.4.3.1.
Oral
13.7.4.3.2.
Intravenous
13.7.4.4.
Rest of
North America Castration-Resistant Prostate Cancer (CRPC) Treatment Market
Revenue (US$ Mn) and Forecasts, By Treatment
13.7.4.4.1.
Hormonal
Therapy
13.7.4.4.2.
Radiation
Therapy
13.7.4.4.2.1. External Beam Radiation Therapy
13.7.4.4.2.2. Systematic Radiation Therapy
13.7.4.4.3.
Chemotherapy
13.7.4.4.4.
Immunotherapy
13.7.4.4.5.
Targeted
Therapy
13.7.4.4.6.
Others
13.7.4.5.
Rest of
North America Castration-Resistant Prostate Cancer (CRPC) Treatment Market
Revenue (US$ Mn) and Forecasts, By End User
13.7.4.5.1.
Hospitals
13.7.4.5.2.
Speciality
Clinics
13.7.4.5.3.
Others
13.8. Key Segment for Channeling Investments
13.8.1. By Country
13.8.2. By Type
13.8.3. By Indication
13.8.4. By Route of Administration
13.8.5. By Treatment
13.8.6. By End User
14. Europe Castration-Resistant Prostate Cancer
(CRPC) Treatment Market Analysis and Forecasts, 2022 – 2030
14.1. Overview
14.1.1. Europe Castration-Resistant Prostate Cancer
(CRPC) Treatment Market Revenue (US$ Mn)
14.2. Europe Castration-Resistant Prostate Cancer
(CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Type
14.2.1. Metastatic CRPC (mCRPC)
14.2.2. Non-Metastatic CRPC (nmCRPC)
14.3. Europe Castration-Resistant Prostate Cancer
(CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Indication
14.3.1. Symptomatic
14.3.2. Mildly Symptomatic
14.3.3. Asymptomatic
14.4. Europe Castration-Resistant Prostate Cancer
(CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.4.1. Oral
14.4.2. Intravenous
14.5. Europe Castration-Resistant Prostate Cancer
(CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment
14.5.1. Hormonal Therapy
14.5.2. Radiation Therapy
14.5.2.1.
External
Beam Radiation Therapy
14.5.2.2.
Systematic
Radiation Therapy
14.5.3. Chemotherapy
14.5.4. Immunotherapy
14.5.5. Targeted Therapy
14.5.6. Others
14.6. Europe Castration-Resistant Prostate Cancer (CRPC)
Treatment Market Revenue (US$ Mn) and Forecasts, By End User
14.6.1. Hospitals
14.6.2. Speciality Clinics
14.6.3. Others
14.7. Europe Castration-Resistant Prostate Cancer
(CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Country
14.7.1. France
14.7.1.1.
France
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
14.7.1.1.1.
Metastatic
CRPC (mCRPC)
14.7.1.1.2.
Non-Metastatic
CRPC (nmCRPC)
14.7.1.2.
France
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Indication
14.7.1.2.1.
Symptomatic
14.7.1.2.2.
Mildly
Symptomatic
14.7.1.2.3.
Asymptomatic
14.7.1.3.
France
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
14.7.1.3.1.
Oral
14.7.1.3.2.
Intravenous
14.7.1.4.
France
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
14.7.1.4.1.
Hormonal
Therapy
14.7.1.4.2.
Radiation
Therapy
14.7.1.4.2.1. External Beam Radiation Therapy
14.7.1.4.2.2. Systematic Radiation Therapy
14.7.1.4.3.
Chemotherapy
14.7.1.4.4.
Immunotherapy
14.7.1.4.5.
Targeted
Therapy
14.7.1.4.6.
Others
14.7.1.5.
France
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By End User
14.7.1.5.1.
Hospitals
14.7.1.5.2.
Speciality
Clinics
14.7.1.5.3.
Others
14.7.2. The UK
14.7.2.1.
The UK
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
14.7.2.1.1.
Metastatic
CRPC (mCRPC)
14.7.2.1.2.
Non-Metastatic
CRPC (nmCRPC)
14.7.2.2.
The UK
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Indication
14.7.2.2.1.
Symptomatic
14.7.2.2.2.
Mildly
Symptomatic
14.7.2.2.3.
Asymptomatic
14.7.2.3.
The UK
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
14.7.2.3.1.
Oral
14.7.2.3.2.
Intravenous
14.7.2.4.
The UK
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
14.7.2.4.1.
Hormonal
Therapy
14.7.2.4.2.
Radiation
Therapy
14.7.2.4.2.1. External Beam Radiation Therapy
14.7.2.4.2.2. Systematic Radiation Therapy
14.7.2.4.3.
Chemotherapy
14.7.2.4.4.
Immunotherapy
14.7.2.4.5.
Targeted
Therapy
14.7.2.4.6.
Others
14.7.2.5.
The UK
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By End User
14.7.2.5.1.
Hospitals
14.7.2.5.2.
Speciality
Clinics
14.7.2.5.3.
Others
14.7.3. Spain
14.7.3.1.
Spain
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
14.7.3.1.1.
Metastatic
CRPC (mCRPC)
14.7.3.1.2.
Non-Metastatic
CRPC (nmCRPC)
14.7.3.2.
Spain
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Indication
14.7.3.2.1.
Symptomatic
14.7.3.2.2.
Mildly
Symptomatic
14.7.3.2.3.
Asymptomatic
14.7.3.3.
Spain
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
14.7.3.3.1.
Oral
14.7.3.3.2.
Intravenous
14.7.3.4.
Spain
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
14.7.3.4.1.
Hormonal
Therapy
14.7.3.4.2.
Radiation
Therapy
14.7.3.4.2.1. External Beam Radiation Therapy
14.7.3.4.2.2. Systematic Radiation Therapy
14.7.3.4.3.
Chemotherapy
14.7.3.4.4.
Immunotherapy
14.7.3.4.5.
Targeted
Therapy
14.7.3.4.6.
Others
14.7.3.5.
Spain
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By End User
14.7.3.5.1.
Hospitals
14.7.3.5.2.
Speciality
Clinics
14.7.3.5.3.
Others
14.7.4. Germany
14.7.4.1.
Germany
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
14.7.4.1.1.
Metastatic
CRPC (mCRPC)
14.7.4.1.2.
Non-Metastatic
CRPC (nmCRPC)
14.7.4.2.
Germany
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Indication
14.7.4.2.1.
Symptomatic
14.7.4.2.2.
Mildly
Symptomatic
14.7.4.2.3.
Asymptomatic
14.7.4.3.
Germany
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
14.7.4.3.1.
Oral
14.7.4.3.2.
Intravenous
14.7.4.4.
Germany
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
14.7.4.4.1.
Hormonal
Therapy
14.7.4.4.2.
Radiation
Therapy
14.7.4.4.2.1. External Beam Radiation Therapy
14.7.4.4.2.2. Systematic Radiation Therapy
14.7.4.4.3.
Chemotherapy
14.7.4.4.4.
Immunotherapy
14.7.4.4.5.
Targeted
Therapy
14.7.4.4.6.
Others
14.7.4.5.
Germany
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By End User
14.7.4.5.1.
Hospitals
14.7.4.5.2.
Speciality
Clinics
14.7.4.5.3.
Others
14.7.5. Italy
14.7.5.1.
Italy
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
14.7.5.1.1.
Metastatic
CRPC (mCRPC)
14.7.5.1.2.
Non-Metastatic
CRPC (nmCRPC)
14.7.5.2.
Italy
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Indication
14.7.5.2.1.
Symptomatic
14.7.5.2.2.
Mildly
Symptomatic
14.7.5.2.3.
Asymptomatic
14.7.5.3.
Italy
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
14.7.5.3.1.
Oral
14.7.5.3.2.
Intravenous
14.7.5.4.
Italy
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
14.7.5.4.1.
Hormonal
Therapy
14.7.5.4.2.
Radiation
Therapy
14.7.5.4.2.1. External Beam Radiation Therapy
14.7.5.4.2.2. Systematic Radiation Therapy
14.7.5.4.3.
Chemotherapy
14.7.5.4.4.
Immunotherapy
14.7.5.4.5.
Targeted
Therapy
14.7.5.4.6.
Others
14.7.5.5.
Italy
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By End User
14.7.5.5.1.
Hospitals
14.7.5.5.2.
Speciality
Clinics
14.7.5.5.3.
Others
14.7.6. Nordic Countries
14.7.6.1.
Nordic
Countries Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Type
14.7.6.1.1.
Metastatic
CRPC (mCRPC)
14.7.6.1.2.
Non-Metastatic
CRPC (nmCRPC)
14.7.6.2.
Nordic
Countries Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
14.7.6.2.1.
Symptomatic
14.7.6.2.2.
Mildly
Symptomatic
14.7.6.2.3.
Asymptomatic
14.7.6.3.
Nordic
Countries Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.7.6.3.1.
Oral
14.7.6.3.2.
Intravenous
14.7.6.4.
Nordic
Countries Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Treatment
14.7.6.4.1.
Hormonal
Therapy
14.7.6.4.2.
Radiation
Therapy
14.7.6.4.2.1. External Beam Radiation Therapy
14.7.6.4.2.2. Systematic Radiation Therapy
14.7.6.4.3.
Chemotherapy
14.7.6.4.4.
Immunotherapy
14.7.6.4.5.
Targeted
Therapy
14.7.6.4.6.
Others
14.7.6.5.
Nordic
Countries Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By End User
14.7.6.5.1.
Hospitals
14.7.6.5.2.
Speciality
Clinics
14.7.6.5.3.
Others
14.7.6.6.
Nordic
Countries Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Country
14.7.6.6.1.
Denmark
14.7.6.6.2.
Finland
14.7.6.6.3.
Iceland
14.7.6.6.4.
Sweden
14.7.6.6.5.
Norway
14.7.7. Benelux Union
14.7.7.1.
Benelux
Union Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$
Mn) and Forecasts, By Type
14.7.7.1.1.
Metastatic
CRPC (mCRPC)
14.7.7.1.2.
Non-Metastatic
CRPC (nmCRPC)
14.7.7.2.
Benelux
Union Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$
Mn) and Forecasts, By Indication
14.7.7.2.1.
Symptomatic
14.7.7.2.2.
Mildly
Symptomatic
14.7.7.2.3.
Asymptomatic
14.7.7.3.
Benelux
Union Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$
Mn) and Forecasts, By Route of Administration
14.7.7.3.1.
Oral
14.7.7.3.2.
Intravenous
14.7.7.4.
Benelux
Union Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$
Mn) and Forecasts, By Treatment
14.7.7.4.1.
Hormonal
Therapy
14.7.7.4.2.
Radiation
Therapy
14.7.7.4.2.1. External Beam Radiation Therapy
14.7.7.4.2.2. Systematic Radiation Therapy
14.7.7.4.3.
Chemotherapy
14.7.7.4.4.
Immunotherapy
14.7.7.4.5.
Targeted
Therapy
14.7.7.4.6.
Others
14.7.7.5.
Benelux
Union Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$
Mn) and Forecasts, By End User
14.7.7.5.1.
Hospitals
14.7.7.5.2.
Speciality
Clinics
14.7.7.5.3.
Others
14.7.7.6.
Benelux
Union Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$
Mn) and Forecasts, By Country
14.7.7.6.1.
Belgium
14.7.7.6.2.
The
Netherlands
14.7.7.6.3.
Luxembourg
14.7.8. Rest of Europe
14.7.8.1.
Rest of
Europe Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Type
14.7.8.1.1.
Metastatic
CRPC (mCRPC)
14.7.8.1.2.
Non-Metastatic
CRPC (nmCRPC)
14.7.8.2.
Rest of
Europe Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
14.7.8.2.1.
Symptomatic
14.7.8.2.2.
Mildly
Symptomatic
14.7.8.2.3.
Asymptomatic
14.7.8.3.
Rest of Europe
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
14.7.8.3.1.
Oral
14.7.8.3.2.
Intravenous
14.7.8.4.
Rest of
Europe Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Treatment
14.7.8.4.1.
Hormonal
Therapy
14.7.8.4.2.
Radiation
Therapy
14.7.8.4.2.1. External Beam Radiation Therapy
14.7.8.4.2.2. Systematic Radiation Therapy
14.7.8.4.3.
Chemotherapy
14.7.8.4.4.
Immunotherapy
14.7.8.4.5.
Targeted
Therapy
14.7.8.4.6.
Others
14.7.8.5.
Rest of
Europe Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By End User
14.7.8.5.1.
Hospitals
14.7.8.5.2.
Speciality
Clinics
14.7.8.5.3.
Others
14.8. Key Segment for Channeling Investments
14.8.1. By Country
14.8.2. By Type
14.8.3. By Indication
14.8.4. By Route of Administration
14.8.5. By Treatment
14.8.6. By End User
15. Asia Pacific Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Analysis and Forecasts, 2022 – 2030
15.1. Overview
15.1.1. Asia Pacific Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn)
15.2. Asia Pacific Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Type
15.2.1. Metastatic CRPC (mCRPC)
15.2.2. Non-Metastatic CRPC (nmCRPC)
15.3. Asia Pacific Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Indication
15.3.1. Symptomatic
15.3.2. Mildly Symptomatic
15.3.3. Asymptomatic
15.4. Asia Pacific Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.4.1. Oral
15.4.2. Intravenous
15.5. Asia Pacific Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment
15.5.1. Hormonal Therapy
15.5.2. Radiation Therapy
15.5.2.1.
External
Beam Radiation Therapy
15.5.2.2.
Systematic
Radiation Therapy
15.5.3. Chemotherapy
15.5.4. Immunotherapy
15.5.5. Targeted Therapy
15.5.6. Others
15.6. Asia Pacific Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By End User
15.6.1. Hospitals
15.6.2. Speciality Clinics
15.6.3. Others
15.7. Asia Pacific Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Country
15.7.1. China
15.7.1.1.
China
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
15.7.1.1.1.
Metastatic
CRPC (mCRPC)
15.7.1.1.2.
Non-Metastatic
CRPC (nmCRPC)
15.7.1.2.
China
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Indication
15.7.1.2.1.
Symptomatic
15.7.1.2.2.
Mildly
Symptomatic
15.7.1.2.3.
Asymptomatic
15.7.1.3.
China
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
15.7.1.3.1.
Oral
15.7.1.3.2.
Intravenous
15.7.1.4.
China
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
15.7.1.4.1.
Hormonal
Therapy
15.7.1.4.2.
Radiation
Therapy
15.7.1.4.2.1. External Beam Radiation Therapy
15.7.1.4.2.2. Systematic Radiation Therapy
15.7.1.4.3.
Chemotherapy
15.7.1.4.4.
Immunotherapy
15.7.1.4.5.
Targeted
Therapy
15.7.1.4.6.
Others
15.7.1.5.
China
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By End User
15.7.1.5.1.
Hospitals
15.7.1.5.2.
Speciality
Clinics
15.7.1.5.3.
Others
15.7.2. Japan
15.7.2.1.
Japan
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
15.7.2.1.1.
Metastatic
CRPC (mCRPC)
15.7.2.1.2.
Non-Metastatic
CRPC (nmCRPC)
15.7.2.2.
Japan
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Indication
15.7.2.2.1.
Symptomatic
15.7.2.2.2.
Mildly
Symptomatic
15.7.2.2.3.
Asymptomatic
15.7.2.3.
Japan
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
15.7.2.3.1.
Oral
15.7.2.3.2.
Intravenous
15.7.2.4.
Japan
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
15.7.2.4.1.
Hormonal
Therapy
15.7.2.4.2.
Radiation
Therapy
15.7.2.4.2.1. External Beam Radiation Therapy
15.7.2.4.2.2. Systematic Radiation Therapy
15.7.2.4.3.
Chemotherapy
15.7.2.4.4.
Immunotherapy
15.7.2.4.5.
Targeted
Therapy
15.7.2.4.6.
Others
15.7.2.5.
Japan
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By End User
15.7.2.5.1.
Hospitals
15.7.2.5.2.
Speciality
Clinics
15.7.2.5.3.
Others
15.7.3. India
15.7.3.1.
India
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
15.7.3.1.1.
Metastatic
CRPC (mCRPC)
15.7.3.1.2.
Non-Metastatic
CRPC (nmCRPC)
15.7.3.2.
India
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Indication
15.7.3.2.1.
Symptomatic
15.7.3.2.2.
Mildly
Symptomatic
15.7.3.2.3.
Asymptomatic
15.7.3.3.
India
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
15.7.3.3.1.
Oral
15.7.3.3.2.
Intravenous
15.7.3.4.
India
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
15.7.3.4.1.
Hormonal
Therapy
15.7.3.4.2.
Radiation
Therapy
15.7.3.4.2.1. External Beam Radiation Therapy
15.7.3.4.2.2. Systematic Radiation Therapy
15.7.3.4.3.
Chemotherapy
15.7.3.4.4.
Immunotherapy
15.7.3.4.5.
Targeted
Therapy
15.7.3.4.6.
Others
15.7.3.5.
India
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By End User
15.7.3.5.1.
Hospitals
15.7.3.5.2.
Speciality
Clinics
15.7.3.5.3.
Others
15.7.4. New Zealand
15.7.4.1.
New
Zealand Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Type
15.7.4.1.1.
Metastatic
CRPC (mCRPC)
15.7.4.1.2.
Non-Metastatic
CRPC (nmCRPC)
15.7.4.2.
New
Zealand Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
15.7.4.2.1.
Symptomatic
15.7.4.2.2.
Mildly
Symptomatic
15.7.4.2.3.
Asymptomatic
15.7.4.3.
New
Zealand Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
15.7.4.3.1.
Oral
15.7.4.3.2.
Intravenous
15.7.4.4.
New Zealand
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
15.7.4.4.1.
Hormonal
Therapy
15.7.4.4.2.
Radiation
Therapy
15.7.4.4.2.1. External Beam Radiation Therapy
15.7.4.4.2.2. Systematic Radiation Therapy
15.7.4.4.3.
Chemotherapy
15.7.4.4.4.
Immunotherapy
15.7.4.4.5.
Targeted
Therapy
15.7.4.4.6.
Others
15.7.4.5.
New
Zealand Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By End User
15.7.4.5.1.
Hospitals
15.7.4.5.2.
Speciality
Clinics
15.7.4.5.3.
Others
15.7.5. Australia
15.7.5.1.
Australia
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
15.7.5.1.1.
Metastatic
CRPC (mCRPC)
15.7.5.1.2.
Non-Metastatic
CRPC (nmCRPC)
15.7.5.2.
Australia
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Indication
15.7.5.2.1.
Symptomatic
15.7.5.2.2.
Mildly
Symptomatic
15.7.5.2.3.
Asymptomatic
15.7.5.3.
Australia
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
15.7.5.3.1.
Oral
15.7.5.3.2.
Intravenous
15.7.5.4.
Australia
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
15.7.5.4.1.
Hormonal
Therapy
15.7.5.4.2.
Radiation
Therapy
15.7.5.4.2.1. External Beam Radiation Therapy
15.7.5.4.2.2. Systematic Radiation Therapy
15.7.5.4.3.
Chemotherapy
15.7.5.4.4.
Immunotherapy
15.7.5.4.5.
Targeted
Therapy
15.7.5.4.6.
Others
15.7.5.5.
Australia
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By End User
15.7.5.5.1.
Hospitals
15.7.5.5.2.
Speciality
Clinics
15.7.5.5.3.
Others
15.7.6. South Korea
15.7.6.1.
South
Korea Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$
Mn) and Forecasts, By Type
15.7.6.1.1.
Metastatic
CRPC (mCRPC)
15.7.6.1.2.
Non-Metastatic
CRPC (nmCRPC)
15.7.6.2.
South
Korea Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$
Mn) and Forecasts, By Indication
15.7.6.2.1.
Symptomatic
15.7.6.2.2.
Mildly
Symptomatic
15.7.6.2.3.
Asymptomatic
15.7.6.3.
South
Korea Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$
Mn) and Forecasts, By Route of Administration
15.7.6.3.1.
Oral
15.7.6.3.2.
Intravenous
15.7.6.4.
South
Korea Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$
Mn) and Forecasts, By Treatment
15.7.6.4.1.
Hormonal
Therapy
15.7.6.4.2.
Radiation
Therapy
15.7.6.4.2.1. External Beam Radiation Therapy
15.7.6.4.2.2. Systematic Radiation Therapy
15.7.6.4.3.
Chemotherapy
15.7.6.4.4.
Immunotherapy
15.7.6.4.5.
Targeted
Therapy
15.7.6.4.6.
Others
15.7.6.5.
South
Korea Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$
Mn) and Forecasts, By End User
15.7.6.5.1.
Hospitals
15.7.6.5.2.
Speciality
Clinics
15.7.6.5.3.
Others
15.7.7. Southeast Asia
15.7.7.1.
Southeast
Asia Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$
Mn) and Forecasts, By Type
15.7.7.1.1.
Metastatic
CRPC (mCRPC)
15.7.7.1.2.
Non-Metastatic
CRPC (nmCRPC)
15.7.7.2.
Southeast
Asia Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$
Mn) and Forecasts, By Indication
15.7.7.2.1.
Symptomatic
15.7.7.2.2.
Mildly
Symptomatic
15.7.7.2.3.
Asymptomatic
15.7.7.3.
Southeast
Asia Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$
Mn) and Forecasts, By Route of Administration
15.7.7.3.1.
Oral
15.7.7.3.2.
Intravenous
15.7.7.4.
Southeast
Asia Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$
Mn) and Forecasts, By Treatment
15.7.7.4.1.
Hormonal
Therapy
15.7.7.4.2.
Radiation
Therapy
15.7.7.4.2.1. External Beam Radiation Therapy
15.7.7.4.2.2. Systematic Radiation Therapy
15.7.7.4.3.
Chemotherapy
15.7.7.4.4.
Immunotherapy
15.7.7.4.5.
Targeted
Therapy
15.7.7.4.6.
Others
15.7.7.5.
Southeast
Asia Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$
Mn) and Forecasts, By End User
15.7.7.5.1.
Hospitals
15.7.7.5.2.
Speciality
Clinics
15.7.7.5.3.
Others
15.7.7.6.
Southeast
Asia Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$
Mn) and Forecasts, By Country
15.7.7.6.1.
Indonesia
15.7.7.6.2.
Thailand
15.7.7.6.3.
Malaysia
15.7.7.6.4.
Singapore
15.7.7.6.5.
Rest of
Southeast Asia
15.7.8. Rest of Asia Pacific
15.7.8.1.
Rest of
Asia Pacific Castration-Resistant Prostate Cancer (CRPC) Treatment Market
Revenue (US$ Mn) and Forecasts, By Type
15.7.8.1.1.
Metastatic
CRPC (mCRPC)
15.7.8.1.2.
Non-Metastatic
CRPC (nmCRPC)
15.7.8.2.
Rest of
Asia Pacific Castration-Resistant Prostate Cancer (CRPC) Treatment Market
Revenue (US$ Mn) and Forecasts, By Indication
15.7.8.2.1.
Symptomatic
15.7.8.2.2.
Mildly
Symptomatic
15.7.8.2.3.
Asymptomatic
15.7.8.3.
Rest of
Asia Pacific Castration-Resistant Prostate Cancer (CRPC) Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.8.3.1.
Oral
15.7.8.3.2.
Intravenous
15.7.8.4.
Rest of
Asia Pacific Castration-Resistant Prostate Cancer (CRPC) Treatment Market
Revenue (US$ Mn) and Forecasts, By Treatment
15.7.8.4.1.
Hormonal
Therapy
15.7.8.4.2.
Radiation
Therapy
15.7.8.4.2.1. External Beam Radiation Therapy
15.7.8.4.2.2. Systematic Radiation Therapy
15.7.8.4.3.
Chemotherapy
15.7.8.4.4.
Immunotherapy
15.7.8.4.5.
Targeted
Therapy
15.7.8.4.6.
Others
15.7.8.5.
Rest of
Asia Pacific Castration-Resistant Prostate Cancer (CRPC) Treatment Market
Revenue (US$ Mn) and Forecasts, By End User
15.7.8.5.1.
Hospitals
15.7.8.5.2.
Speciality
Clinics
15.7.8.5.3.
Others
15.8. Key Segment for Channeling Investments
15.8.1. By Country
15.8.2. By Type
15.8.3. By Indication
15.8.4. By Route of Administration
15.8.5. By Treatment
15.8.6. By End User
16. Middle East and Africa Castration-Resistant
Prostate Cancer (CRPC) Treatment Market Analysis and Forecasts, 2022 – 2030
16.1. Overview
16.1.1. Middle East and Africa Castration-Resistant
Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
16.2. Middle East and Africa Castration-Resistant
Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Type
16.2.1. Metastatic CRPC (mCRPC)
16.2.2. Non-Metastatic CRPC (nmCRPC)
16.3. Middle East and Africa Castration-Resistant
Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By
Indication
16.3.1. Symptomatic
16.3.2. Mildly Symptomatic
16.3.3. Asymptomatic
16.4. Middle East and Africa Castration-Resistant
Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
16.4.1. Oral
16.4.2. Intravenous
16.5. Middle East and Africa Castration-Resistant
Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment
16.5.1. Hormonal Therapy
16.5.2. Radiation Therapy
16.5.2.1.
External
Beam Radiation Therapy
16.5.2.2.
Systematic
Radiation Therapy
16.5.3. Chemotherapy
16.5.4. Immunotherapy
16.5.5. Targeted Therapy
16.5.6. Others
16.6. Middle East and Africa Castration-Resistant
Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By End
User
16.6.1. Hospitals
16.6.2. Speciality Clinics
16.6.3. Others
16.7. Middle East and Africa Castration-Resistant
Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By
Country
16.7.1. Saudi Arabia
16.7.1.1.
Saudi
Arabia Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Type
16.7.1.1.1.
Metastatic
CRPC (mCRPC)
16.7.1.1.2.
Non-Metastatic
CRPC (nmCRPC)
16.7.1.2.
Saudi
Arabia Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
16.7.1.2.1.
Symptomatic
16.7.1.2.2.
Mildly
Symptomatic
16.7.1.2.3.
Asymptomatic
16.7.1.3.
Saudi
Arabia Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
16.7.1.3.1.
Oral
16.7.1.3.2.
Intravenous
16.7.1.4.
Saudi
Arabia Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Treatment
16.7.1.4.1.
Hormonal
Therapy
16.7.1.4.2.
Radiation
Therapy
16.7.1.4.2.1. External Beam Radiation Therapy
16.7.1.4.2.2. Systematic Radiation Therapy
16.7.1.4.3.
Chemotherapy
16.7.1.4.4.
Immunotherapy
16.7.1.4.5.
Targeted
Therapy
16.7.1.4.6.
Others
16.7.1.5.
Saudi
Arabia Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By End User
16.7.1.5.1.
Hospitals
16.7.1.5.2.
Speciality
Clinics
16.7.1.5.3.
Others
16.7.2. UAE
16.7.2.1.
UAE
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
16.7.2.1.1.
Metastatic
CRPC (mCRPC)
16.7.2.1.2.
Non-Metastatic
CRPC (nmCRPC)
16.7.2.2.
UAE
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Indication
16.7.2.2.1.
Symptomatic
16.7.2.2.2.
Mildly
Symptomatic
16.7.2.2.3.
Asymptomatic
16.7.2.3.
UAE
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
16.7.2.3.1.
Oral
16.7.2.3.2.
Intravenous
16.7.2.4.
UAE
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
16.7.2.4.1.
Hormonal
Therapy
16.7.2.4.2.
Radiation
Therapy
16.7.2.4.2.1. External Beam Radiation Therapy
16.7.2.4.2.2. Systematic Radiation Therapy
16.7.2.4.3.
Chemotherapy
16.7.2.4.4.
Immunotherapy
16.7.2.4.5.
Targeted
Therapy
16.7.2.4.6.
Others
16.7.2.5.
UAE
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By End User
16.7.2.5.1.
Hospitals
16.7.2.5.2.
Speciality
Clinics
16.7.2.5.3.
Others
16.7.3. Egypt
16.7.3.1.
Egypt
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
16.7.3.1.1.
Metastatic
CRPC (mCRPC)
16.7.3.1.2.
Non-Metastatic
CRPC (nmCRPC)
16.7.3.2.
Egypt
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Indication
16.7.3.2.1.
Symptomatic
16.7.3.2.2.
Mildly
Symptomatic
16.7.3.2.3.
Asymptomatic
16.7.3.3.
Egypt
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
16.7.3.3.1.
Oral
16.7.3.3.2.
Intravenous
16.7.3.4.
Egypt
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
16.7.3.4.1.
Hormonal
Therapy
16.7.3.4.2.
Radiation
Therapy
16.7.3.4.2.1. External Beam Radiation Therapy
16.7.3.4.2.2. Systematic Radiation Therapy
16.7.3.4.3.
Chemotherapy
16.7.3.4.4.
Immunotherapy
16.7.3.4.5.
Targeted
Therapy
16.7.3.4.6.
Others
16.7.3.5.
Egypt
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By End User
16.7.3.5.1.
Hospitals
16.7.3.5.2.
Speciality
Clinics
16.7.3.5.3.
Others
16.7.4. Kuwait
16.7.4.1.
Kuwait
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
16.7.4.1.1.
Metastatic
CRPC (mCRPC)
16.7.4.1.2.
Non-Metastatic
CRPC (nmCRPC)
16.7.4.2.
Kuwait
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Indication
16.7.4.2.1.
Symptomatic
16.7.4.2.2.
Mildly
Symptomatic
16.7.4.2.3.
Asymptomatic
16.7.4.3.
Kuwait
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
16.7.4.3.1.
Oral
16.7.4.3.2.
Intravenous
16.7.4.4.
Kuwait
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
16.7.4.4.1.
Hormonal
Therapy
16.7.4.4.2.
Radiation
Therapy
16.7.4.4.2.1. External Beam Radiation Therapy
16.7.4.4.2.2. Systematic Radiation Therapy
16.7.4.4.3.
Chemotherapy
16.7.4.4.4.
Immunotherapy
16.7.4.4.5.
Targeted
Therapy
16.7.4.4.6.
Others
16.7.4.5.
Kuwait
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn) and
Forecasts, By End User
16.7.4.5.1.
Hospitals
16.7.4.5.2.
Speciality
Clinics
16.7.4.5.3.
Others
16.7.5. South Africa
16.7.5.1.
South
Africa Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Type
16.7.5.1.1.
Metastatic
CRPC (mCRPC)
16.7.5.1.2.
Non-Metastatic
CRPC (nmCRPC)
16.7.5.2.
South
Africa Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
16.7.5.2.1.
Symptomatic
16.7.5.2.2.
Mildly
Symptomatic
16.7.5.2.3.
Asymptomatic
16.7.5.3.
South
Africa Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
16.7.5.3.1.
Oral
16.7.5.3.2.
Intravenous
16.7.5.4.
South
Africa Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By Treatment
16.7.5.4.1.
Hormonal
Therapy
16.7.5.4.2.
Radiation
Therapy
16.7.5.4.2.1. External Beam Radiation Therapy
16.7.5.4.2.2. Systematic Radiation Therapy
16.7.5.4.3.
Chemotherapy
16.7.5.4.4.
Immunotherapy
16.7.5.4.5.
Targeted
Therapy
16.7.5.4.6.
Others
16.7.5.5.
South
Africa Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue
(US$ Mn) and Forecasts, By End User
16.7.5.5.1.
Hospitals
16.7.5.5.2.
Speciality
Clinics
16.7.5.5.3.
Others
16.7.6. Rest of Middle East & Africa
16.7.6.1.
Rest of
Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) Treatment
Market Revenue (US$ Mn) and Forecasts, By Type
16.7.6.1.1.
Metastatic
CRPC (mCRPC)
16.7.6.1.2.
Non-Metastatic
CRPC (nmCRPC)
16.7.6.2.
Rest of
Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) Treatment
Market Revenue (US$ Mn) and Forecasts, By Indication
16.7.6.2.1.
Symptomatic
16.7.6.2.2.
Mildly
Symptomatic
16.7.6.2.3.
Asymptomatic
16.7.6.3.
Rest of
Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) Treatment
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.7.6.3.1.
Oral
16.7.6.3.2.
Intravenous
16.7.6.4.
Rest of
Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) Treatment
Market Revenue (US$ Mn) and Forecasts, By Treatment
16.7.6.4.1.
Hormonal
Therapy
16.7.6.4.2.
Radiation
Therapy
16.7.6.4.2.1. External Beam Radiation Therapy
16.7.6.4.2.2. Systematic Radiation Therapy
16.7.6.4.3.
Chemotherapy
16.7.6.4.4.
Immunotherapy
16.7.6.4.5.
Targeted
Therapy
16.7.6.4.6.
Others
16.7.6.5.
Rest of
Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) Treatment
Market Revenue (US$ Mn) and Forecasts, By End User
16.7.6.5.1.
Hospitals
16.7.6.5.2.
Speciality
Clinics
16.7.6.5.3.
Others
16.8. Key Segment for Channeling Investments
16.8.1. By Country
16.8.2. By Type
16.8.3. By Indication
16.8.4. By Route of Administration
16.8.5. By Treatment
16.8.6. By End User
17. Latin America Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Analysis and Forecasts, 2022 – 2030
17.1. Overview
17.1.1. Latin America Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn)
17.2. Latin America Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Type
17.2.1. Metastatic CRPC (mCRPC)
17.2.2. Non-Metastatic CRPC (nmCRPC)
17.3. Latin America Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Indication
17.3.1. Symptomatic
17.3.2. Mildly Symptomatic
17.3.3. Asymptomatic
17.4. Latin America Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
17.4.1. Oral
17.4.2. Intravenous
17.5. Latin America Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment
17.5.1. Hormonal Therapy
17.5.2. Radiation Therapy
17.5.2.1.
External
Beam Radiation Therapy
17.5.2.2.
Systematic
Radiation Therapy
17.5.3. Chemotherapy
17.5.4. Immunotherapy
17.5.5. Targeted Therapy
17.5.6. Others
17.6. Latin America Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By End User
17.6.1. Hospitals
17.6.2. Speciality Clinics
17.6.3. Others
17.7. Latin America Castration-Resistant Prostate
Cancer (CRPC) Treatment Market Revenue (US$ Mn) and Forecasts, By Country
17.7.1. Brazil
17.7.1.1.
Brazil
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
17.7.1.1.1.
Metastatic
CRPC (mCRPC)
17.7.1.1.2.
Non-Metastatic
CRPC (nmCRPC)
17.7.1.2.
Brazil
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Indication
17.7.1.2.1.
Symptomatic
17.7.1.2.2.
Mildly
Symptomatic
17.7.1.2.3.
Asymptomatic
17.7.1.3.
Brazil
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
17.7.1.3.1.
Oral
17.7.1.3.2.
Intravenous
17.7.1.4.
Brazil
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
17.7.1.4.1.
Hormonal
Therapy
17.7.1.4.2.
Radiation
Therapy
17.7.1.4.2.1. External Beam Radiation Therapy
17.7.1.4.2.2. Systematic Radiation Therapy
17.7.1.4.3.
Chemotherapy
17.7.1.4.4.
Immunotherapy
17.7.1.4.5.
Targeted
Therapy
17.7.1.4.6.
Others
17.7.1.5.
Brazil
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By End User
17.7.1.5.1.
Hospitals
17.7.1.5.2.
Speciality
Clinics
17.7.1.5.3.
Others
17.7.2. Argentina
17.7.2.1.
Argentina
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Type
17.7.2.1.1.
Metastatic
CRPC (mCRPC)
17.7.2.1.2.
Non-Metastatic
CRPC (nmCRPC)
17.7.2.2.
Argentina
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Indication
17.7.2.2.1.
Symptomatic
17.7.2.2.2.
Mildly
Symptomatic
17.7.2.2.3.
Asymptomatic
17.7.2.3.
Argentina
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
17.7.2.3.1.
Oral
17.7.2.3.2.
Intravenous
17.7.2.4.
Argentina
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
17.7.2.4.1.
Hormonal
Therapy
17.7.2.4.2.
Radiation
Therapy
17.7.2.4.2.1. External Beam Radiation Therapy
17.7.2.4.2.2. Systematic Radiation Therapy
17.7.2.4.3.
Chemotherapy
17.7.2.4.4.
Immunotherapy
17.7.2.4.5.
Targeted
Therapy
17.7.2.4.6.
Others
17.7.2.5.
Argentina
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Revenue (US$ Mn)
and Forecasts, By End User
17.7.2.5.1.
Hospitals
17.7.2.5.2.
Speciality
Clinics
17.7.2.5.3.
Others
17.7.3. Rest of Latin America
17.7.3.1.
Rest of
Latin America Castration-Resistant Prostate Cancer (CRPC) Treatment Market
Revenue (US$ Mn) and Forecasts, By Type
17.7.3.1.1.
Metastatic
CRPC (mCRPC)
17.7.3.1.2.
Non-Metastatic
CRPC (nmCRPC)
17.7.3.2.
Rest of
Latin America Castration-Resistant Prostate Cancer (CRPC) Treatment Market
Revenue (US$ Mn) and Forecasts, By Indication
17.7.3.2.1.
Symptomatic
17.7.3.2.2.
Mildly
Symptomatic
17.7.3.2.3.
Asymptomatic
17.7.3.3.
Rest of
Latin America Castration-Resistant Prostate Cancer (CRPC) Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
17.7.3.3.1.
Oral
17.7.3.3.2.
Intravenous
17.7.3.4.
Rest of
Latin America Castration-Resistant Prostate Cancer (CRPC) Treatment Market
Revenue (US$ Mn) and Forecasts, By Treatment
17.7.3.4.1.
Hormonal
Therapy
17.7.3.4.2.
Radiation
Therapy
17.7.3.4.2.1. External Beam Radiation Therapy
17.7.3.4.2.2. Systematic Radiation Therapy
17.7.3.4.3.
Chemotherapy
17.7.3.4.4.
Immunotherapy
17.7.3.4.5.
Targeted
Therapy
17.7.3.4.6.
Others
17.7.3.5.
Rest of
Latin America Castration-Resistant Prostate Cancer (CRPC) Treatment Market
Revenue (US$ Mn) and Forecasts, By End User
17.7.3.5.1.
Hospitals
17.7.3.5.2.
Speciality
Clinics
17.7.3.5.3.
Others
17.8. Key Segment for Channeling Investments
17.8.1. By Country
17.8.2. By Type
17.8.3. By Indication
17.8.4. By Route of Administration
17.8.5. By Treatment
17.8.6. By End User
18. Competitive Benchmarking
18.1. Brand Benchmarking
18.2. Market Share Analysis, 2021
18.3. Global Presence and Growth Strategies
18.3.1. Mergers and Acquisitions
18.3.2. Product Launches
18.3.3. Investments Trends
18.3.4. R&D Initiatives
19. Player Profiles
19.1. Astellas Pharma Inc.
19.1.1. Company Details
19.1.2. Company Overview
19.1.3. Product Offerings
19.1.4. Key Developments
19.1.5. Financial Analysis
19.1.6. SWOT Analysis
19.1.7. Business Strategies
19.2.
Bayer
AG
19.2.1. Company Details
19.2.2. Company Overview
19.2.3. Product Offerings
19.2.4. Key Developments
19.2.5. Financial Analysis
19.2.6. SWOT Analysis
19.2.7. Business Strategies
19.3.
Pfizer,
Inc.
19.3.1. Company Details
19.3.2. Company Overview
19.3.3. Product Offerings
19.3.4. Key Developments
19.3.5. Financial Analysis
19.3.6. SWOT Analysis
19.3.7. Business Strategies
19.4.
Johnson
& Johnson Services, Inc (Xian Janssen Pharmaceutical Ltd.)
19.4.1. Company Details
19.4.2. Company Overview
19.4.3. Product Offerings
19.4.4. Key Developments
19.4.5. Financial Analysis
19.4.6. SWOT Analysis
19.4.7. Business Strategies
19.5.
Sanofi
19.5.1. Company Details
19.5.2. Company Overview
19.5.3. Product Offerings
19.5.4. Key Developments
19.5.5. Financial Analysis
19.5.6. SWOT Analysis
19.5.7. Business Strategies
19.6. Other Market Participants
20. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
